COMMUNIQUÉS West-GlobeNewswire

EnteroBiotix announces positive Phase 2 TrIuMPH results supporting EBX-102-02 as a potential first-in-class, oral, full-spectrum microbiome therapy for irritable bowel syndrome
08/01/2026
Clinically meaningful improvements in global IBS symptom severity observed as early as Week 1 and sustained through Week 7, with EBX-102-02 outperforming placebo throughout the study (final assessment at Week 7) Durable [...]
Agomab Announces Positive Phase 1 Interim Results with AGMB-447 in Healthy Participants and Initiation of Idiopathic Pulmonary Fibrosis Cohort
08/01/2026
-- Interim data from Phase 1 with single and multiple ascending doses show no safety signals and a generally favorable tolerability profile of AGMB-447 in healthy participants -- -- Pharmacokinetic profile in healthy [...]
Orion Pharma announces the initiation of TEADES Phase 2 trial of ODM-212 in Malignant Pleural Mesothelioma (MPM) and Epithelioid Hemangioendothelioma (EHE)
08/01/2026
ORION CORPORATION PRESS RELEASE 8 JANUARY 2026 at 12.00 EET Orion Pharma announces the initiation of TEADES Phase 2 trial of ODM-212 in Malignant Pleural Mesothelioma (MPM) and Epithelioid Hemangioendothelioma (EHE) [...]
Human Appeal’s new subsidiary, The Waqf Fund, launched into $700 billion global market
08/01/2026
To promote charitable funds for long-term humanitarian projects MANCHESTER, United Kingdom, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Leading UK humanitarian aid charity, Human Appeal, today announces the launch of a new [...]
Aclarion Provides 2025 Update and 2026 Corporate Outlook
08/01/2026
Quarterly Nociscan scan volumes increased 114% year-over-year in Q4 2025 Annual Nociscan scan volumes increased 69% year-over-year in 2025 Debt-free balance sheet with $12.0 million in cash as of December 31, 2025, [...]
Telix to Present Pipeline and Commercial Portfolio Overview at J.P. Morgan Healthcare Conference
08/01/2026
MELBOURNE, Australia and INDIANAPOLIS, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today advises that Dr. Christian Behrenbruch, Managing Director and Group CEO, will [...]
Pharming Group reports preliminary 2025 revenues and announces Investor Day
08/01/2026
Leiden, The Netherlands, January 8, 2026: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) today announced its preliminary, unaudited revenues for the full year 2025 and plans [...]
Basilea provides portfolio update and outlook
08/01/2026
Clinical portfolio strengthened through the in-licensing of phase 3-ready antibiotic ceftibuten-ledaborbactam Fosmanogepix second phase 3 study initiated; two phase 3 studies in invasive fungal infections progressing as [...]
Eleva appoints Erich Rajkovic as new Chief Business Officer
08/01/2026
Freiburg im Breisgau, Germany – January 8, 2026 – Eleva, a pioneer in discovering and developing previously inaccessible biologics, today announced the appointment of Dr. Erich Rajkovic, MBA, as Chief Business Officer. [...]
Tensive reports positive pivotal trial top-line results showing REGENERA™ bioresorbable device may transform breast reconstruction
08/01/2026
Clinical data from pivotal trial in patients undergoing lumpectomy confirm strong safety profile and growing performance benefits Primary safety endpoint met and encouraging secondary performance objectives at 6 months [...]
CMR Surgical receives CE Mark for use of Versius in paediatric surgery
08/01/2026
Small, modular design of the Versius system supports use in robotic-assisted paediatric surgery Cambridge, UK – 8 January 2026, CMR Surgical (‘CMR’ or ‘the Company’), the global surgical robotics business, today [...]
Santhera Licenses AGAMREE® (Vamorolone) to Nxera Pharma in Japan, South Korea, Australia and New Zealand in a Deal Valued at up to USD 205 Million Plus Royalties
08/01/2026
Ad hoc announcement pursuant to Art. 53 LR Exclusive licensing agreement includes USD 40 million upfront comprising USD 30 million in cash and USD 10 million equity investment at CHF 14.91 per share, a 20% premium to [...]
Nxera Pharma Licenses Japan and Select Asia-Pacific Rights to Vamorolone for Duchenne Muscular Dystrophy from Santhera Pharmaceuticals
08/01/2026
Vamorolone is approved and marketed as AGAMREE® for the treatment of Duchenne Muscular Dystrophy (DMD) in the US, European Union, UK and China New five-year data on vamorolone highlighted substantially improved safety [...]
Bright Minds Biosciences Announces Pricing of Upsized US$175 Million Public Offering of Common Stock
08/01/2026
NEW YORK, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (“ Bright Minds ” or the “ Company ”) announces the pricing of its previously announced public offering of 1,945,000 [...]
Conavi Medical Corp. Announces Filing of Amended & Restated Final Prospectus
08/01/2026
NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES A&R FINAL PROSPECTUS WILL BE ACCESSIBLE ON SEDAR+ TORONTO, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Conavi Medical Corp. (TSXV: CNVI [...]
Phathom Pharmaceuticals Announces Pricing of $130 Million Public Offering of Common Stock and Pre-Funded Warrants
08/01/2026
FLORHAM PARK, N.J., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) [...]
Alumis Announces Pricing of Upsized Public Offering of Common Stock
08/01/2026
SOUTH SAN FRANCISCO, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing next-generation targeted therapies for patients with immune-mediated [...]
Best Oral Peptides for Weight Loss: Injectable vs Sublingual vs Daily Pill – Direct Meds Consumer Analysis
08/01/2026
January 2026 Wellness Season: Format Comparison for Needle-Free GLP-1 Options, Administration Preferences, and Telehealth Access Pathways HOUSTON, TX, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Disclaimer: This article is for [...]
Immuneering Announces Exceptional 64% Overall Survival At 12 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP
07/01/2026
- Reported 12-month overall survival (OS) in Phase 2a clinical trial nearly double the benchmark from pivotal study of standard of care gemcitabine/nab-paclitaxel (GnP) - - Atebimetinib consistently demonstrates [...]

Pages